ALOX12 and Myocardial fibrosis: Importantly, the occurrence of myocardial fibrosis has been known to hinder the treatment efficacy of ERT drugs during the long course of FC [11], suggesting an additional therapeutic regimen such as Alox12/15 pharmacological inhibition is required to improve conventional treatment in patients with poor responses to ERT.